IL141766A0 - 2-methyl-thieno-benzodiazepine formulation - Google Patents

2-methyl-thieno-benzodiazepine formulation

Info

Publication number
IL141766A0
IL141766A0 IL14176699A IL14176699A IL141766A0 IL 141766 A0 IL141766 A0 IL 141766A0 IL 14176699 A IL14176699 A IL 14176699A IL 14176699 A IL14176699 A IL 14176699A IL 141766 A0 IL141766 A0 IL 141766A0
Authority
IL
Israel
Prior art keywords
thieno
methyl
olanzapine
benzodiazepine formulation
formulation
Prior art date
Application number
IL14176699A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/163,769 external-priority patent/US6169084B1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL141766A0 publication Critical patent/IL141766A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14176699A 1998-09-30 1999-03-24 2-methyl-thieno-benzodiazepine formulation IL141766A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16376898A 1998-09-30 1998-09-30
US09/163,769 US6169084B1 (en) 1997-09-30 1998-09-30 2-methyl-thieno-benzodiazepine formulation
PCT/US1999/006417 WO2000018408A1 (en) 1998-09-30 1999-03-24 2-methyl-thieno-benzodiazepine formulation

Publications (1)

Publication Number Publication Date
IL141766A0 true IL141766A0 (en) 2002-03-10

Family

ID=26859927

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14176699A IL141766A0 (en) 1998-09-30 1999-03-24 2-methyl-thieno-benzodiazepine formulation
IL141766A IL141766A (en) 1998-09-30 2001-03-01 Olanzapine pamoate, solvates thereof and medicaments comprising them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL141766A IL141766A (en) 1998-09-30 2001-03-01 Olanzapine pamoate, solvates thereof and medicaments comprising them

Country Status (28)

Country Link
EP (1) EP1119359B1 (de)
JP (1) JP4551988B2 (de)
CN (1) CN1146422C (de)
AT (2) ATE267602T1 (de)
AU (1) AU759751B2 (de)
BR (1) BR9914156A (de)
CA (1) CA2344873A1 (de)
CZ (1) CZ302367B6 (de)
DE (2) DE69935873T2 (de)
DK (2) DK1468689T3 (de)
EA (1) EA002580B1 (de)
ES (2) ES2285294T3 (de)
GE (1) GEP20094818B (de)
HK (1) HK1041199B (de)
HR (1) HRP20010238B1 (de)
HU (1) HU227400B1 (de)
ID (1) ID29574A (de)
IL (2) IL141766A0 (de)
MY (1) MY126476A (de)
NO (1) NO328243B1 (de)
NZ (1) NZ510208A (de)
PL (1) PL196821B1 (de)
PT (2) PT1119359E (de)
SK (1) SK285944B6 (de)
TR (1) TR200100885T2 (de)
TW (1) TW577890B (de)
UA (1) UA66872C2 (de)
WO (1) WO2000018408A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
AU779452B2 (en) * 1999-12-28 2005-01-27 Cipla Limited New polymorphic forms of olanzapine
PL196814B1 (pl) * 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
WO2006006185A1 (en) * 2004-07-14 2006-01-19 Shasun Chemicals And Drugs Limited Improved process for making form i of olanzapine.
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
EP1838716B1 (de) * 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapinpamoat-dihydrat
CZ299218B6 (cs) * 2006-11-07 2008-05-21 Zentiva, A. S. Kompozice depotních olanzapinových injekcních systému
FR2927965B1 (fr) * 2008-02-22 2010-06-04 Valeo Materiaux De Friction Sa Procede de fabrication d'un materiau de friction et notamment d'une couronne de friction d'embrayage.
EP2501225B1 (de) * 2009-11-16 2017-11-01 Ipsen Pharma S.A.S. Pharmazeutische zusammensetzung aus melanocortinrezeptorliganden
WO2011091142A2 (en) * 2010-01-20 2011-07-28 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of olanzapine pamoate
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
WO2014125500A1 (en) 2013-02-13 2014-08-21 Neuland Laboratories Limited A process for preparation of olanzapine pamoate
CN105044231B (zh) * 2015-06-27 2022-09-13 万特制药(海南)有限公司 一种分离测定奥氮平双羟萘酸盐一水合物有关物质的方法
CA3057438A1 (en) * 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation
DK0669128T3 (da) * 1992-11-17 2000-06-19 Yoshitomi Pharmaceutical Sustained-release mikrosfære indeholdende antipsykotikum og fremgangsmåde til at fremstille samme
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
CZ299247B6 (cs) * 1996-09-23 2008-05-28 Eli Lilly And Company Olanzapin dihydrát D
EP1018880A4 (de) * 1997-09-30 2006-06-14 Lilly Co Eli 2-methyl-thieno-benzodiazepin-formulierung

Also Published As

Publication number Publication date
AU3362799A (en) 2000-04-17
DE69935873T2 (de) 2008-01-10
PT1119359E (pt) 2004-08-31
WO2000018408A1 (en) 2000-04-06
ES2221376T3 (es) 2004-12-16
EP1119359A1 (de) 2001-08-01
HU227400B1 (en) 2011-05-30
SK4162001A3 (en) 2002-03-05
CA2344873A1 (en) 2000-04-06
JP2002525330A (ja) 2002-08-13
PT1468689E (pt) 2007-07-09
DE69917663T2 (de) 2005-05-25
EP1119359A4 (de) 2001-12-19
NZ510208A (en) 2003-04-29
BR9914156A (pt) 2001-06-26
DK1468689T3 (da) 2007-08-13
CZ302367B6 (cs) 2011-04-13
CZ20011149A3 (cs) 2002-01-16
NO328243B1 (no) 2010-01-11
EA002580B1 (ru) 2002-06-27
MY126476A (en) 2006-10-31
HRP20010238B1 (en) 2006-05-31
UA66872C2 (uk) 2004-06-15
SK285944B6 (sk) 2007-11-02
ATE267602T1 (de) 2004-06-15
EP1119359B1 (de) 2004-05-26
CN1146422C (zh) 2004-04-21
CN1320038A (zh) 2001-10-31
DK1119359T3 (da) 2004-08-16
DE69917663D1 (de) 2004-07-01
NO20011583L (no) 2001-03-28
GEP20094818B (en) 2009-11-10
HUP0103636A2 (hu) 2002-01-28
HK1041199A1 (en) 2002-07-05
HUP0103636A3 (en) 2003-05-28
TW577890B (en) 2004-03-01
NO20011583D0 (no) 2001-03-28
EA200100406A1 (ru) 2001-10-22
TR200100885T2 (tr) 2001-08-21
PL196821B1 (pl) 2008-02-29
JP4551988B2 (ja) 2010-09-29
DE69935873D1 (de) 2007-05-31
ID29574A (id) 2001-09-06
IL141766A (en) 2006-12-31
HRP20010238A2 (en) 2002-04-30
ES2285294T3 (es) 2007-11-16
ATE359793T1 (de) 2007-05-15
AU759751B2 (en) 2003-05-01
PL346981A1 (en) 2002-03-11
HK1041199B (zh) 2005-03-18

Similar Documents

Publication Publication Date Title
CA2304568A1 (en) Olanzapine pamoate formulations
HK1041199A1 (en) 2-Methyl-thieno-benzodiazepine formulation.
YU15299A (sh) Farmaceutski sastavi
MY125467A (en) Olanzapine dihydrate d
AP9901534A0 (en) Pharmaceutical formulations.
HUP0100779A3 (en) Novel derivatives of 3,3-diphenylpropylamines
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
AU5873498A (en) Mutant (msbb) or (htrb) genes
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
PL330277A1 (en) Derivatives of 2,4-diaminopyrimidine
PL342060A1 (en) Derivatives of 1,3,4-oxadiaxolone
EP1073447A4 (de) N1 modifizierte glycopeptide
AU4415797A (en) New pde iv inhibitors: "bis-compounds"
AU4544099A (en) Novel therapeutic agents for macromolecular structures
EP1136072A4 (de) Zubereitung zur verabreichung in den harnleiter
WO2000007544A3 (en) Vitronectin receptor antagonists
HU9802500D0 (en) Pocess for the preparation of periodates
PL347770A1 (en) Composition for the parenteral administration of active agents
MX9606009A (es) Uso de 8,9-deshidroestrona como un antioxidante.
JO1909B1 (en) Composition of 2-methylthenio-benzodiazepine oral
JO2087B1 (en) Pharmacy combinations
ECSP992901A (es) Formulacion de 2- metil -tieno benzodiazepina
ZA997361B (en) Cultivation of pastures.
ZA9811564B (en) Derivatives of 1,3,4-oxadiazolone

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed